%0 Journal Article %T What next for preimplantation genetic screening? More randomized controlled trials needed? %+ Center for Reproductive Medicine %+ Center for Preimplantation Genetic Diagnosis %+ Institut de génétique et biologie moléculaire et cellulaire (IGBMC) %+ Service de Biologie de la Reproduction–Syndicat Inter-Hospitalier de la Communauté Urbaine de Strasbourg %+ Faculté de Médecine %A Mastenbroek, Sebastiaan %A Scriven, Paul %A Twisk, Moniek %A Viville, Stéphane %A van Der Veen, Fulco %A Repping, Sjoerd %< avec comité de lecture %@ 0268-1161 %J Human Reproduction %I Oxford University Press (OUP) %V 23 %N 12 %P 2626-8 %8 2008-12 %D 2008 %R 10.1093/humrep/den376 %M 18948310 %Z Life Sciences [q-bio]/Biochemistry, Molecular BiologyJournal articles %X The recent debate on preimplantation genetic screening (PGS) has raised questions about its routine use in clinical practice. It has been suggested that the most effective way to resolve the debate about the usefulness of PGS is to perform more well-designed and well-executed randomized controlled trials (RCTs). However, in view of the lack of evidence for the effectiveness of PGS and the accumulating evidence for its harmfulness, it is our opinion that it is unethical to perform additional RCTs for the indication advanced maternal age using cleavage stage biopsy. %G English %L inserm-00350813 %U https://inserm.hal.science/inserm-00350813 %~ INSERM %~ CNRS %~ UNIV-STRASBG1 %~ IGBMC %~ UNIV-STRASBG %~ SITE-ALSACE